3-alpha-hydroxy-5beta-cholestanol,
epicoprostanol,
Epicoprostanol,
epi-Coprostanol,
Epicoprosterol,
Epikoprosterin,
epi-Coprosterol,
5beta-Cholestan-3alpha-ol,
516-92-7,
UNII-UFH3K1F9EG,
.alpha.-Coprostanol,
(3alpha,5beta)-cholestan-3-ol,
NSC 18182,
UFH3K1F9EG,
5.beta.-Cholestan-3.alpha.-ol,
NCGC00167541-01,
5beta-Cholestan-3alpha-ol, >=95%,
5betaCholestan-3alpha-ol,
Coprostan-3.alpha.-ol,
Cholestan-3-ol, (3alpha,5beta)- (9CI),
AC1L3M4M,
DSSTox_CID_26700,
DSSTox_RID_81834,
DSSTox_GSID_46700,
5-beta-Cholestan-3-alpha-ol,
Cholestan-3-ol, (3a,5b)-,
CHEMBL1998721,
DTXSID7046700,
CTK1H0779,
QYIXCDOBOSTCEI-KKFSNPNRSA-N,
NSC18182,
ZINC4683759,
Tox21_112538,
LMST04030110,
MFCD00064143,
NSC-18182,
(3.alpha.,5.beta.)-Cholestan-3-ol,
CAS-516-92-7,
CC-21229,
Cholestan-3-ol, (3.alpha.,5.beta.)-,
C-25636,
Epicoprostanol, United States Pharmacopeia (USP) Reference Standard,
(3R,5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol,
Dihydrocholesterol,
5b-cholestan-3a-ol,
Cholestan-3-ol,5.beta.)-,
C32H58O,
CID91465,
AR-1G7252,
C32-H58-O,
52809-10-6,